论文部分内容阅读
[目的]探讨前列腺癌(PCa)患者血清腺激肽释放酶2(human kallikrein 2,hK2)检测的临床意义。[方法]采用酶联免疫吸附试验(ELISA)和放射免疫分析法(RIA)分别检测30例PCa、30例前列腺增生(BPH)患者和30名健康人血清hK2和前列腺特异性抗原(PSA)的水平。并随访12例行根治性前列腺全切术后PCa患者hK2水平。[结果]PCa组hK2水平为78.8±25.2ng/L,明显高于BPH组(25.4±6.28ng/L)和健康组(24.1±4.16ng/L),差异有统计学意义(P<0.001);BPH组与健康组比较差异无统计学意义(P>0.05);hK2检测PCa的敏感度、特异性、准确率分别为63.3%,90.0%,76.6%;血清hK2诊断PCa的ROC曲线下面积为0.767(95%CI:0.642~0.891);12例PCa患者手术前和手术后hK2比较差异有统计学意义(81.5±24.8ng/L vs 38.4±13.5ng/L,P<0.001)。[结论]血清hk2诊断PCa,可能可以提高其特异性,减少不必要的活检率,有望成为新的PCa检测指标预测高危人群。
[Objective] To investigate the clinical significance of detecting serum kallikrein 2 (hK2) in patients with prostate cancer (PCa). [Methods] Thirty cases of PCa, 30 cases of benign prostatic hyperplasia (BPH) and 30 healthy individuals were detected by enzyme - linked immunosorbent assay (ELISA) and radioimmunoassay (RIA). Serum hK2 and PSA Level. The hK2 levels in PCa patients after radical prostatectomy were followed up. [Results] The hK2 level in PCa group was 78.8 ± 25.2ng / L, which was significantly higher than that in BPH group (25.4 ± 6.28ng / L) and healthy group (24.1 ± 4.16ng / L) (P <0.001) (P> 0.05). The sensitivity, specificity and accuracy of hK2 in detecting PCa were 63.3%, 90.0% and 76.6% respectively. The area under ROC curve of serum hK2 in diagnosing PCa was significantly lower than that in healthy group Was 0.767 (95% CI: 0.642-0.891). There was significant difference in hK2 between preoperative and postoperative in 12 PCa patients (81.5 ± 24.8ng vs 38.4 ± 13.5ng / L, P <0.001). [Conclusion] The diagnosis of PCa by serum hk2 may improve the specificity and reduce the unnecessary biopsy rate, which is expected to become a new predictor of PCa in high risk population.